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Abstract
Aims: The mdx mouse has proven to be useful in understanding the cardiomyopathy that frequently occurs in muscular
dystrophy patients. Here we employed a comprehensive array of clinically relevant in vivo MRI techniques to identify early
markers of cardiac dysfunction and follow disease progression in the hearts of mdx mice.
Methods and Results: Serial measurements of cardiac morphology and function were made in the same group of mdx mice
and controls (housed in a non-SPF facility) using MRI at 1, 3, 6, 9 and 12 months after birth. Left ventricular (LV) and right
ventricular (RV) systolic and diastolic function, response to dobutamine stress and myocardial fibrosis were assessed. RV
dysfunction preceded LV dysfunction, with RV end systolic volumes increased and RV ejection fractions reduced at 3
months of age. LV ejection fractions were reduced at 12 months, compared with controls. An abnormal response to
dobutamine stress was identified in the RV of mdx mice as early as 1 month. Late-gadolinium-enhanced MRI identified
increased levels of myocardial fibrosis in 6, 9 and 12-month-old mdx mice, the extent of fibrosis correlating with the degree
of cardiac remodeling and hypertrophy.
Conclusions: MRI could identify cardiac abnormalities in the RV of mdx mice as young as 1 month, and detected myocardial
fibrosis at 6 months. We believe these to be the earliest MRI measurements of cardiac function reported for any mice, and
the first use of late-gadolinium-enhancement in a mouse model of congenital cardiomyopathy. These techniques offer a
sensitive and clinically relevant in vivo method for assessment of cardiomyopathy caused by muscular dystrophy and other
diseases.
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Introduction
Duchenne muscular dystrophy (DMD) is a progressive muscle
wasting disease that affects approximately one in 3000 males [1,2].
The absence of functional dystrophin restricts interaction and
signal transduction between the cytoskeleton and the extracellular
matrix in both skeletal muscle cells and cardiomyocytes [2,3].
Advances in the treatment of respiratory failure in DMD patients
has increased their life expectancy, but has resulted in many
patients developing cardiomyopathy [2]. In the dystrophic heart,
cytoskeleton dysfunction can lead to cell membrane rupture,
cardiomyocyte necrosis and replacement of contractile myocardi-
um with fibrotic tissue. This increases wall stress, reduces cardiac
function and can lead to heart failure [2,4]. Current treatments,
including ACE inhibitors and b-blockers, slow disease progression,
but the disease remains incurable.
The mdx mouse model of muscular dystrophy has been
extensively studied [5,6,7,8,9,10,11,12,13,14,15] and, although
exhibiting a mild form of muscular dystrophy, has been useful for
studying pathological mechanisms, disease progression and
therapy [4,5,6,7,8,9,10,11,12,13,14,16,17,18,19]. Novel gene,
antisense oligonucleotide and cell therapies have been used to
increase levels of dystrophin and restore skeletal and cardiac
muscle function in the mdx mouse [4,6,11,16,19]. Antisense
oligonucleotide therapy, already tested in patients, has shown
promise for increasing synthesis of functional dystrophin [17,20].
The development of non-invasive imaging methods that can
provide accurate characterization of the efficacy of new therapeu-
tic strategies in mice and humans will help translate such
important therapies to the clinic.
Cardiac magnetic resonance imaging and echocardiography
have been used to identify increased end systolic volumes and
reduced ejection fractions in the right and left ventricles of
muscular dystrophy patients [21,22,23]. Late gadolinium-en-
hanced (LGE) MR imaging has been used to identify fibrotic or
inflamed tissue in the intraventricular septum, RV insertion points
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and anterolateral wall of the left ventricle [21,22,24,25,26,27,28].
Importantly, prognosis and cardiac function are poorer in DMD
patients who have late gadolinium enhancement [24,28].
In the mdx mouse, standard measures of left ventricular function,
including ejection fraction, end systolic volume and wall thickening,
do not become abnormal until 9 to 11 months of age [8,13].
However, MRI has identified early abnormalities in cardiac wall
strain and torsion [7], as well as right ventricular dysfunction at 6–8
months [6,13]. Imaging studies of cardiac function in the mdx
mouse have focused on mice at one specific age, or imaged different
groups of mice at different ages, the earliest time point being ,5-
months [5,6,7,8,12,13]. Here we serially imaged the same group of
male mdx mice and littermate male wild type controls using MRI at
1 month after birth and at four further timepoints up to 1 year. We
assessed left and right ventricular systolic function, diastolic function
and response to dobutamine stress. Further, we report the first use of
late gadolinium enhancement to identify regions of myocardial
fibrosis in mdx mice. In vivo measures of fibrosis correlated with
cardiac function, and may offer a sensitive and clinically relevant in
vivo method for assessing the efficacy of experimental treatments for
muscular dystrophy.
Methods
The study conformed to EU Directive 2010/63/EU and was
approved by The University of Oxford Animal Ethics Review
Committees and the Home Office (London, UK) under Project
License 30/2278. Ten male mdx and 12 male wild type C57Blk10
mice were housed in a non-SPF (specific pathogen free) facility,
had free access to food and water and underwent serial cardiac
MRI at 1, 3, 6, 9 and 12 months of age.
Cardiac cine-MRI
Cardiac cine-MRI was performed as described [29,30]. Briefly,
mice were anesthetized with 1.5% isoflurane in O2 and positioned
supine in a purpose-built cradle. ECG electrodes were inserted
into the forepaws and a respiration loop was taped across the
chest. The cradle was lowered into a vertical-bore, 11.7 T MR
system (Magnex Scientific, Oxon, United Kingdom) with a 40 mm
birdcage coil (Rapid Biomedical, Wu¨rzburg, Germany) and a
Bruker console running Paravision 2.1.1 (Bruker Medical,
Ettlingen, Germany). A stack of contiguous 1 mm thick true
short-axis ECG and respiration-gated cine-FLASH images (TE/
TR 1.43/4.6 ms; 17.5u pulse; field of view 25.6625.6 mm; matrix
size 2566256; voxel size 100610061000 mm; 20 to 30 frames per
cardiac cycle) were acquired to cover the entire left and right
ventricles of 3 to 12-month-old mice. For 1-month-old mice, a
28 mm birdcage coil (Rapid Biomedical) was used, with slice
thickness 0.75 mm, field of view 19.2619.2 mm; matrix size
1926192; voxel size 10061006750 mm. Long-axis two-chamber
and four-chamber images were also acquired.
High temporal resolution cine-MRI
High temporal resolution cine-MRI was performed in a single mid
LV short axis slice as described [30]. Briefly, ECG gated cine-FLASH
images (TE/TR 0.86/2.4 ms; 60u pulse; field of view 25.6625.6 mm;
matrix size 1286128; voxel size 200620061000 mm; 40 to 60 frames
per cardiac cycle) were acquired over two consecutive cardiac cycles
providing data throughout diastole to determine peak ejection and
filling rates.
Late gadolinium-enhanced MRI
Late gadolinium-enhanced MRI (LGE-MRI) was performed to
cover the entire LV at 10 to 25 min after intra-peritoneal injection
of 0.5 mmol/kg Gd-DTPA using the same cardiac and respiratory
gated, gradient echo cine-FLASH sequence (TE/TR 1.43/4.6 ms;
,60u pulse; field of view 25.6625.6 mm; matrix size 2566256),
but with increased flip angle to saturate signal in the normal
myocardium. This method is similar to that validated by Protti et al
[31].
Dobutamine stress MRI
Dobutamine stress testing was performed in 1, 3 and 6-month-
old mice. An intra-peritoneal injection of 1.5 mg/kg of dobuta-
mine was given whilst mice were still positioned in the scanner.
Heart rate typically increased within 2 minutes of the injection,
stabilized at 5 minutes and remained elevated for over 30 minutes.
Once the heart rate had stabilized, 3 representative cine-FLASH
MR images (basal, mid LV and apical) were acquired in the same
locations as prior to dobutamine. Changes in volumes and ejection
fraction are reported as the sum of these 3 slices. The entire in vivo
imaging protocol was performed in approximately 70 minutes.
Stress testing was not performed in 9 and 12 month mice as it
caused mortality in older mice (DJS-unpublished).
MRI data analysis
Image analysis was performed using ImageJ (NIH Image,
Bethesda, MD). Left ventricular mass, volumes and ejection fraction
were calculated as described [32]. Right ventricular volumes were
calculated from the same stack of short axis cine images, but 2–3
extra slices at the base of the heart were required to cover the entire
RV, as described by Wiesmann et al [33]. Wall thickness was
measured at end diastole and end systole in the interventricular
septum and the LV free wall in a mid-LV slice. LV ejection and
filling rates were calculated from chamber volume measurements
made in every frame of the high temporal resolution cine images
using a semi-automated function in ImageJ [30]. Rates were
calculated as the difference in volume over 3 consecutive frames
divided by the time to acquire the frames as described [30].
In vivo late gadolinium-enhanced MR images were thresholded
to two standard deviations above the mean signal intensity from
remote tissue. Location and extent of hyper-enhancement were
manually assessed and segmented.
Histological analysis
After 1 and 15 months, mice were sacrificed by cervical
dislocation, hearts were excised, perfused with saline and frozen in
TissueTek OCT. Cryosections (10 mm) were cut and stained for
collagen using sirius red.
Data and statistical analysis
Results are shown as mean 6 standard error. Differences were
considered significant at p,0.05 using 2 way ANOVA.
Results
Serial measurements of resting cardiac morphology and
function
Mice were generally healthy and active throughout the study.
However, after 9 months, the mortality in mdx mice increased,
with 2 mice dying under anaesthesia and 3 more dying in the next
2 months (Figure 1). Mdx mice had increased body mass at 3, 6
and 9 months compared with wild type (WT) controls (Table 1).
Heart rates under anaesthesia were similar in mdx and control
mice. However, anaesthetic levels during imaging were adjusted to
maintain heart rate at ,500 bpm, potentially masking patholog-
ical differences.
Serial MRI of the mdx Mouse Heart
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Cine-MRI was used to measure left and right ventricular
morphology and function in mdx and WT mice from 1 to 12
months of age. Good quality images were obtained even from the
smallest of the 1 month old mice weighing less than 10 g
(Figure 2).
No alterations to left ventricular mass, septal and free wall
thickness and thickening, end diastolic volume (EDV), end systolic
volume (ESV), stroke volume (SV) or ejection fraction (EF) were
identified in mdx mice before 9 months (Figure 1, Table 1).
Cardiac output (CO) was lower in mdx mice at 6 and 9 months.
SV was reduced at 9 months, but not at 12 months. However,
there was a significant decrease in ejection fraction by 12 months
in mdx mouse hearts. Measurements of rate of change in LV
volume during contraction and relaxation using high temporal
resolution cine-MRI, showed that peak ejection and peak filling
rates were also lower in 3 and 6 month old mdx mice (Table 1).
Right ventricular ESV was higher and EF was lower in mdx
mice by 3 months, a difference that was maintained at 6, 9 and 12
months (Figure 1, Table 1).
Serial measurements of cardiac function under
dobutamine stress
Administration of dobutamine to 1, 3 and 6-month-old WT
mice increased heart rate by ,20% in 1-month-old mice,
although the increase became less with age (Table 2). Left
ventricular EDV and ESV were reduced and EF was increased in
response to dobutamine. A similar response was observed in mdx
mice (Table 2). Septal and free wall thickness and thickening were
increased to a similar degree in mdx and WT mice at each time
point. In both mdx and WT mice, peak ejection rates increased
under dobutamine stress, whereas peak filling rates were reduced
(Figure 3, Table 2).
An opposite response to dobutamine was observed in the right
ventricle, with EDV and ESV increased and EF reduced (Table 2).
As early as 1 month of age there was a greater increase in RV ESV
in mdx mice after dobutamine compared with WT mice. By 3
months, both ESV and EDV were increased under dobutamine
stress relative to WT.
In vivo identification of myocardial fibrosis in mdx mouse
hearts using late gadolinium-enhanced MRI
Small regions of mid-myocardial late gadolinium enhancement
were identified in the septum of four of nine mdx mice imaged at 6
months (Figure 4). By 9 months, four mice showed septal late
gadolinium enhancement (not shown). At 12 months all six mdx
mice displayed varying degrees of late gadolinium enhancement in
the septum or RV insertion points (Figure 4). Late gadolinium
enhancement was not identified in wild type control mice at any
time point. The diffuse nature of the fibrosis made it difficult to
accurately segment the volume of late gadolinium enhancement,
but the number of imaging slices that showed enhancement could
be calculated and indicated that greater cardiac remodeling and
hypertrophy was present in hearts that displayed more late
gadolinium enhancement (Figure 5). There also appeared to be
late gadolinium enhancement in the RV wall of 12-month-old
mdx mice (Figure 4). However, the spatial resolution of the
imaging technique used had limited ability to visualize the thin RV
wall, making the true location of the enhancement uncertain.
Tissue sections stained for sirius red confirmed the presence of
fibrotic tissue within the intra-ventricular septum as well as
Figure 1. Serial measurements of cardiac function and mortality. A–E; Graphs of left and right ventricular morphology and function
measured in vivo in mdx and WT mice from 1 to 12 months. F; Kaplein-Meier graph of mouse survival during the study indicating earlier mortality in
mdx mice.
doi:10.1371/journal.pone.0028569.g001
Serial MRI of the mdx Mouse Heart
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extensive fibrosis in the right ventricular wall (Figure 4). Only
small, non localized areas of fibrosis were identified in a few of the
sections from the LV free wall. No fibrosis was identified in
sections taken from 1-month-old mdx mice (Figure S1).
Discussion
In vivo MRI of mouse models of human cardiac disease can give
valuable insights into pathology and therapy. Although the mdx
mouse model of muscular dystrophy has been studied using
ultrasound and haemodynamic measurements [5,8,11,12,18,19],
there are limited data from MRI studies [6,7,13] and no reports of
serial MR imaging of disease progression in the same mdx mice
over time. Clinically and experimentally, cardiac MRI is more
sensitive to small alterations in cardiac function than other
imaging modalities, including ultrasound [22,34,35]. Hence, we
anticipated that the application of MRI to the mdx mouse, known
to have only mild cardiomyopathy when young [5,8,11,12,18,19],
may identify subtle changes previously missed by other techniques.
In agreement with previous reports [5,6,7,8,9,10,11,12],
standard cine-MRI did not show altered resting LV function in
mdx mice until 9 months of age. However, high temporal
resolution cine-MRI indicated that peak LV filling and ejection
rates were lower at 3 and 6 months of age, suggesting impaired
systolic and diastolic function even in young animals, as has been
Table 1. Left and right ventricular cardiac morphology and function.
1 month 3 months 6 months 9 months 12 months
Body mass (g) Con 1461 2962 3162 3261 3561
mdx 1461 3162 3362 36±1* 3661
Heart mass:body mass con 3.761 3.461 3.761 3.961 3.961
ratio (61023 ) mdx 3.961 3.561 3.561 3.2±1* 3.861
Heart rate (bpm) con 438611 527617 503610 46464 519616
mdx 421617 520612 497612 469612 505611
Left ventricle
End diastolic volume (ul) con 3663 6562 6864 7864 7364
mdx 3763 6563 6064 6864 7466
End systolic volume (ul) con 1361 2661 2462 3264 3063
mdx 1462 2662 2162 3063 3564
Stroke volume (ul) con 2362 3962 4462 4661 4262
mdx 2362 3862 3963 38±2* 3863
Ejection fraction (%) con 6562 6062 6562 6063 5962
mdx 6263 6062 6461 5763 53±2*
Cardiac output con 1461 2161 2261 2261 2261
mdx 1261 2061 18±1* 18±1* 19±1*
Peak filling rate con - 444640 479668 566666 376670
mdx - 375±40* 312±37* 5746121 379670
Peak ejection rate con - 231469 2343635 2411642 2343622
mdx - 2267±14* 2329±31* 2397646 2290617
Mass (mg) con 5264 9963 11662 12564 13564
mdx 5465 10964 11665 11864 13563
Wall thickness
Septum at diastole (mm) con 0.8461 0.9561 1.1361 1.0461 1.2062
mdx 0.8461 0.8861 1.1762 1.0361 1.2661
Free wall at diastole (mm) con 0.7263 0.8863 0.9764 0.9063 1.0464
mdx 0.7063 0.8663 1.0764 0.9663 1.0565
Right ventricle
End diastolic volume (ul) con 3262 6062 6762 6263 7966
mdx 2363 6263 7265 7263 8665
End systolic volume (ul) con 961 1962 2262 2162 3463
mdx 961 25±3* 33±5* 30±3* 47±3*
Stroke volume (ul) con 2361 4062 4561 4161 4563
mdx 2262 3762 3962 4162 3963
Ejection fraction (%) con 7262 6862 6761 6662 5762
mdx 7163 60±3* 56±3* 58±2* 45±2*
Results are presented as means 6 SEM.
doi:10.1371/journal.pone.0028569.t001
Serial MRI of the mdx Mouse Heart
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observed ex vivo in isolated, working 3-month-old mdx mouse
hearts [36] and in vivo in 8-month-old mice [13]. Interestingly,
differences in LV filling and ejection rates were not detected at 12
months, suggesting that progressive remodeling and hypertrophy
may compensate for dysfunction and mask the original abnor-
malities at later time points. This is supported by the study of Li et
al [7], which reported increased regional strain and torsion in the
2-month-old mdx mouse heart and reduced torsion by 10 months.
All mice used in this study were male; female mice may have given
different results [15].
We have reported RV dysfunction in mdx mice at 8 months
that precedes LV dysfunction [13], probably owing to pulmonary
hypertension and dysfunction of the diaphragm muscle [10]. Here,
by performing serial imaging, we were able to determine that
resting RV function was unaltered at 1 month, but abnormal as
early as three months, with RV-ESV increased and RV-EF
reduced. Right ventricular dilatation occurs in DMD patients at
between 16 and 23 years of age [2,26] secondary to pulmonary
hypertension resulting from hypoxia-mediated constriction of
pulmonary arterioles [6]. The size and complex geometry of the
RV makes accurate and reproducible measurement of volume
difficult when using two dimensional ultrasound or low resolution
nuclear imaging methods. High resolution MRI provides the best
method for in vivo assessment of RV function in mice [33] as it can
acquire volumetric images across the entire RV, avoiding
geometric calculation of volume. The ability of MRI to identify
early alterations to RV function in the mdx mouse may offer a
useful marker for assessing disease development and response to
therapy.
Cardiac stress testing has been widely used to identify cardiac
abnormalities that were undetectable at rest [19,37,38,39], and
can highlight ischemia-induced wall motion abnormalities,
hibernating myocardium and contractile reserve [37,38,39]. There
are several methods for performing stress testing in small animals,
including intravenous infusion of increasing doses of drug until
pump failure [19] and a bolus, inter-peritoneal injection of a lower
drug dose that is still capable of increasing cardiac work [38,39].
As we have shown that low dose dobutamine MRI is able to
identify abnormalities in a mouse model of dilated cardiomyop-
athy [38], the latter method was employed here to avoid mortality
that would (necessarily) compromise a serial imaging study.
Dobutamine stress testing of 1, 3 and 6 month mice reduced left
ventricular EDV and ESV and increased EF and septal and free
wall thickness and thickening to a similar degree in WT and mdx
mice. This is the first report of stress testing in 1-month-old mdx
mice, but previous studies conducted on older mice have reported
reduced contractile reserve, measured using hemodynamics
[8,18,19]. This difference may be a reflection of the high and
often lethal levels of beta-adrenergic stimulation used by others. In
Figure 2. Cardiac MRI. In vivo short axis cine-MR images of the same wild type and mdx mouse imaged at 1, 3, 6, 9 and 12 months.
doi:10.1371/journal.pone.0028569.g002
Table 2. Left and right ventricular cardiac function under
dobutamine stress.
% change with
dobutamine 1 month 3 months 6 months
Left ventricle
End diastolic volume con 21264 22163 21464
mdx 21564 22665 22564
End systolic volume con 23668 25066 23866
mdx 23667 25566 24869
Stroke volume con 367 2162 064
mdx 165 2765 21264
Ejection fraction con 1061 1663 1162
mdx 1061 1661 1264
Peak filling rate con 22167 24064 24064
mdx 21065 22365 25365
Peak ejection rate con 21062 2664 2564
mdx 21563 21065 21965
Right ventricle
End diastolic volume con 12610 20623 1465
mdx 30612 52±25* 2365
End systolic volume con 5615 60616 39615
mdx 49±23* 92±14* 40615
Stroke volume con 16610 2167 167
mdx 2368 27±10* 5612
Ejection fraction con 361 21063 2763
mdx 2262 21062 2864
Heart rate (%) con 1965 963 562
mdx 2365 762 462
Results are presented as means 6 SEM.
(note: dobutamine stress increased mortality in older mdx mice).
doi:10.1371/journal.pone.0028569.t002
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both mdx and WT mice, peak ejection rates increased under
dobutamine stress, whilst peak filling rates were reduced. It is
unclear why peak filling rate would decrease under stress, but it
may reflect the lower EDV of dobutamine-stimulated hearts.
However, SV was not altered and the shape of the dV/dt curves
showed a widening of the high velocity filling phases of the cardiac
cycle with partial fusion of the early and atrial components in some
mice (Figure 3).
Dobutamine stress revealed right ventricular dysfunction. To
our knowledge, there are no reports of stress testing of right
ventricular function in mice. We found that EDV and ESV
increased and EF reduced with stress. This suggests that the LV
response to dobutamine increased RV return and elevated RV
pressure. We frequently observed septal bowing during peak
dobutamine stress, indicative of increased RV pressures. As
contractility of the RV was not elevated to the same level as the
LV, the RV dilated and consequentially EF was reduced, in
agreement with clinical reports [40]. As early as 1 month of age
there was a greater increase in RV-ESV in mdx mice after
dobutamine compared with WT. By 3 months, both ESV and
EDV were increased under dobutamine stress relative to WT.
However, these differences did not persist at 9 months, probably
owing to the reduced response to dobutamine in 9-month-old
mice. It is unclear whether this stress-induced abnormality is
directly due to the effect of dobutamine on the heart (possible
through stress-induced ischemic dysfunction [41]), or indirectly
caused by an altered response of the diaphragm, which shows
increased contractility with dobutamine [42] and could influence
RV function. This stress-mediated elevation in RV-ESV is the
earliest reported in vivo measurement of abnormal cardiac
function in the mdx mouse and may indicate that, even at a
very early age, pulmonary and diaphragm dysfunction can induce
RV dysfunction.
Over the past decade late gadolinium-enhanced MRI has
become established as one of the most useful techniques for non-
invasive measurement of myocardial viability [43,44,45,46,47,48].
In recent years late gadolinium-enhanced MRI has been able to
detect fibrosis in patients with hypertrophic [49] and dilated [50]
cardiomyopathy, systemic vasculitus [43], arrhythmogenic right
ventricular disease [45] and DMD [25,26,27] and Becker
muscular dystrophy [22,27].
Late gadolinium-enhanced MRI methods have been developed
for imaging mice post myocardial infarction [31,51], but to date
no studies of congenital cardiomyopathies have been reported. We
detected late gadolinium enhancement in 3 out of 9 mdx mice of 6
Figure 4. Late gadolinium enhancement in 6 and 12 month mdx mice. Upper left; late gadolinium enhancement in 3 of 9 mdx mice at 6
months (arrows). Lower panel; late gadolinium enhancement was present in the septum of all mdx mice imaged at 12 months in both long axis (left)
and short axis (right) views as well as RV wall (arrows). Upper right; no late gadolinium enhancement was present in wild type mice (WT) at any time
point. Far right; Sirius red staining of cryosections confirmed presence of fibrosis in the septum and RV wall of mdx mouse hearts.
doi:10.1371/journal.pone.0028569.g004
Figure 3. Left ventricular filling and ejection rates in control
mouse. Time-volume curve (upper) and rate of change of volume curve
(lower) acquired before and after bolus injection of 1.5 mg/kg
dobutamine. The dobutamine induced an increase in peak ejection
rate, but a reduction in peak filling rate, with lengthening of the high
velocity filling phase. Mdx and control mice showed similar responses.
doi:10.1371/journal.pone.0028569.g003
Serial MRI of the mdx Mouse Heart
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months of age. By 12 months of age, all mdx mice displayed some
late gadolinium enhancement. No late gadolinium enhancement
was identified in control mice. Similar to clinical reports [24,28],
the extent of late gadolinium enhancement correlated with the
degree of cardiac impairment and remodeling. Histology has
shown that fibrosis develops in the hearts of mdx mice from 6
months [12], the extent related to impairment of cardiac function
[5]. The in vivo methods presented here will be useful in assessing
the efficacy of gene therapy studies in the mdx mouse
[4,6,11,16,19].
This study highlights the power of comprehensive and serial
non-invasive imaging for assessment of cardiac function in
experimental models of human disease. The detection of
abnormalities in young mice gives important information
regarding the speed of disease progression and response to
therapy. To our knowledge, there have been no reports of cardiac
MR imaging in mice as young as one month. Many transgenic
animals develop cardiac abnormalities at an early age and may not
survive adolescence. The results presented here demonstrate that it
is feasible to image one-month-old mice and detect early
alterations in function that could be valuable in characterization
of animal models of human cardiac disease. Further, we show that
small animal MRI measurements are directly comparable to those
made in patients, increasing the relevance of pre-clinical data and
speeding translation of novel therapies.
Supporting Information
Figure S1 Sirius red staining of cryosections from 1-
month-old mdx mice (n=3) did not detect any fibrosis in
the LV or RV walls.
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